Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sorafenib
Drug ID BADD_D02058
Description Sorafenib (rINN), marketed as Nexavar by Bayer, is a drug approved for the treatment of advanced renal cell carcinoma (primary kidney cancer). It has also received "Fast Track" designation by the FDA for the treatment of advanced hepatocellular carcinoma (primary liver cancer), and has since performed well in Phase III trials. Sorafenib is a small molecular inhibitor of Raf kinase, PDGF (platelet-derived growth factor), VEGF receptor 2 & 3 kinases and c Kit the receptor for Stem cell factor. A growing number of drugs target most of these pathways. The originality of Sorafenib lays in its simultaneous targeting of the Raf/Mek/Erk pathway.
Indications and Usage Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
Marketing Status Prescription
ATC Code L01EX02
DrugBank ID DB00398
KEGG ID D08524
MeSH ID D000077157
PubChem ID 216239
TTD Drug ID D0W5HK
NDC Product Code 0378-1201; 68554-0073; 12527-8488; 63850-8051; 47049-848; 50419-488; 43744-545
Synonyms Sorafenib | Nexavar | BAY 43-9006 | BAY 43 9006 | BAY 439006 | Sorafenib N-Oxide | Sorafenib N Oxide | BAY-673472 | BAY 673472 | BAY 545-9085 | BAY 545 9085 | BAY 5459085 | BAY-545-9085 | BAY5459085 | Sorafenib Tosylate | 4-(4-(3-(4-Chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxylic acid methyamide-4-methylbenzenesulfonate
Chemical Information
Molecular Formula C21H16ClF3N4O3
CAS Registry Number 284461-73-0
SMILES CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Coronary artery occlusion24.04.04.013; 02.02.01.0060.000799%Not Available
Cough22.02.03.0010.015718%
Cyst16.02.02.002; 08.03.05.0010.000533%Not Available
Cystitis20.03.02.002; 11.01.14.0010.001332%
Deafness04.02.01.0010.001332%Not Available
Death08.04.01.0010.028286%
Decreased activity19.11.01.002; 08.01.01.0060.001598%Not Available
Decubitus ulcer23.03.11.0060.001332%Not Available
Dehydration14.05.05.0010.017050%
Delirium19.13.02.001--
Dementia19.20.02.001; 17.03.01.001--Not Available
Dental caries07.09.01.0010.000533%
Depressed level of consciousness17.02.04.002--
Depressed mood19.15.02.001--Not Available
Depression19.15.01.001--
Dermal cyst23.10.02.001; 16.26.02.0010.000799%Not Available
Dermatitis23.03.04.0020.002664%Not Available
Dermatitis allergic23.03.04.003; 10.01.03.0140.000799%Not Available
Dermatitis bullous23.03.01.0020.000799%
Dermatitis exfoliative10.01.01.004; 23.03.07.001--
Diabetes insipidus14.05.07.003; 05.03.03.0040.000533%Not Available
Diabetes mellitus14.06.01.001; 05.06.01.001--Not Available
Diabetes mellitus inadequate control14.06.01.004; 05.06.01.0040.000533%Not Available
Diabetic neuropathy05.07.04.003; 17.09.04.002; 14.07.04.0030.000533%Not Available
Diarrhoea07.02.01.0010.162244%
Diplopia06.02.06.002; 17.17.01.005--Not Available
Discomfort08.01.08.003--Not Available
Disorientation19.13.01.002; 17.02.05.0150.005328%Not Available
Disseminated intravascular coagulation01.01.02.002; 24.01.01.0100.000903%
Disturbance in attention19.21.02.002; 17.03.03.001--
The 6th Page    First    Pre   6 7 8 9 10    Next   Last    Total 33 Pages